Combination therapy with enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) was associated with durable responses and ...

Perioperative durvalumab has “the potential to transform the standard of care” for patients with muscle-invasive bladder ...

Standard treatment for muscle-invasive bladder cancer is neoadjuvant chemotherapy followed by ... durvalumab combined with neoadjuvant gemcitabine–cisplatin (followed by radical surgery ...

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve ...

The accelerated approval of Trodelvy for patients with metastatic urothelial cancer has been voluntarily withdrawn.

Immunotherapy improved overall survival when added to cisplatin-gemcitabine ... selection of chemotherapy backbones in immunotherapy regimens for mUC [metastatic urothelial cancer], promoting ...

The TROP2-directed antibody-drug conjugate failed to top chemotherapy at extending the lives of bladder cancer patients who had tried a PD-1/L1 therapy and chemo. Detailed data of that flop have ...

Module 1 Selected Case Studies: NUC-3373 plus pembrolizumab in patients with advanced solid tumors: 72-year-old patient with urothelial bladder cancer who had previously received gemcitabine plus ...

These abnormal cells can divide and spread to other body parts, which leads to cancer. Chemotherapy is a treatment that uses medicine to get rid of cancer cells. Chemo doesn't only target cancer ...

Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for BALVERSA®▼ (erdafitinib) as a monotherapy for the treatment ...